saba glp 1 reviews GLP-1s for Type 1s Glucagon-like peptide-1 receptor agonists and

doi: 10.1177/0091270009339189

Liraglutide is recommended at a starting dose of 0.6 mg daily for the first week, followed by an upward titration to 1.2 mg daily

Regulation of hypothalamo-pituitary-adrenocortical responses to stressors by the nucleus of the solitary tract/dorsal vagal complex

Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system

They also decrease the release of IL-33 through which inflammatory Th2 are reduced and IL-5 and 13 are released, leading to a reduced number of eosinophils and reduced goblet metaplasia and mucus production (Figure 2) [53]